XILIO THERAPEUTICS, INC.(XLO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XLO XILIO THERAPEUTICS, INC.

Closed 01-16 16:00:00 EST

0.6401

+0.0000

0.00%

盘后0.6441

+0.0040+0.62%

18:51 EST

High0.6500	Low0.6341	Vol132.88K
Open0.6500	D1 Closing0.6401	Amplitude2.48%
Mkt Cap43.23M	Tradable Cap23.32M	Total Shares67.54M
T/O85.28K	T/O Rate0.36%	Tradable Shares36.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XLO","market":"US","secType":"STK","nameCN":"XILIO THERAPEUTICS, INC.","latestPrice":0.6401,"timestamp":1768597200000,"preClose":0.6401,"halted":0,"volume":132882,"hourTrading":{"tag":"盘后","latestPrice":0.6441,"preClose":0.6401,"latestTime":"18:51 EST","volume":4614,"amount":2969.2452,"timestamp":1768607516496},"delay":0,"floatShares":36436400,"shares":67540900,"eps":-0.61,"marketStatus":"Closed","change":0,"latestTime":"01-16 16:00:00 EST","open":0.65,"high":0.65,"low":0.6341,"amount":85278.16096991999,"amplitude":0.02484,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.61,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":5,"adr":0,"listingDate":1634875200000,"exchange":"NASDAQ","adjPreClose":0.6401,"preHourTrading":{"tag":"盘前","latestPrice":0.6475,"preClose":0.6401,"latestTime":"09:09 EST","volume":15,"amount":9.712499999999999,"timestamp":1768572585434},"postHourTrading":{"tag":"盘后","latestPrice":0.6441,"preClose":0.6401,"latestTime":"18:51 EST","volume":4614,"amount":2969.2452,"timestamp":1768607516496},"volumeRatio":0.39348},"requestUrl":"/m/hq/s/XLO/wiki","defaultTab":"wiki","newsList":[{"id":"2604991964","title":"Xilio Therapeutics Inc. Announces Date for Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2604991964","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604991964?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:06","pubTimestamp":1768597589,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics Inc. has announced that a special meeting of stockholders will be held online. During the meeting, stockholders will consider and vote on proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board of directors or by a stockholder of record on the record date for the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL3H0927:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139"],"gpt_icon":0},{"id":"2601367292","title":"Xilio Therapeutics Announces Leadership Transition and Pipeline Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2601367292","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601367292?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:55","pubTimestamp":1767880537,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics ( ($XLO) ) has provided an announcement. On January 8, 2026, Xilio Therapeutics reported a series of corporate and pipeline upda...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xilio-therapeutics-announces-leadership-transition-and-pipeline-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xilio-therapeutics-announces-leadership-transition-and-pipeline-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","BK4539","LENZ","XLO"],"gpt_icon":0},{"id":"2601367599","title":"BRIEF-Xilio Therapeutics Inc  Appoints Sara Bonstein As Chair Of Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2601367599","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601367599?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:52","pubTimestamp":1767880321,"startTime":"0","endTime":"0","summary":"BRIEF-Xilio Therapeutics Inc  Appoints Sara Bonstein As Chair Of BoardJan 8 (Reuters) - Xilio Therapeutics Inc XLO.O:XILIO THERAPEUTICS INC - APPOINTS SARA BONSTEIN AS CHAIR OF BOARDSource text: ID:nGNXMHLsmFurther company coverage: XLO.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y9112:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139"],"gpt_icon":0},{"id":"2601186362","title":"Xilio Therapeutics Inc - Appoints Sara Bonstein as Chair of Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2601186362","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601186362?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:32","pubTimestamp":1767879172,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y9112:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2601362991","title":"Xilio Therapeutics Raises $35.8 Million Through Series B Warrant Exercises","url":"https://stock-news.laohu8.com/highlight/detail?id=2601362991","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601362991?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:30","pubTimestamp":1767879013,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics Inc. announced the receipt of $35.8 million in gross proceeds from the exercise of Series B warrants. The exercise included full participation by Coastlands Capital, Frazier Life Sciences, and Gilead Sciences, Inc. The Series B warrants were originally issued in connection with a follow-on public offering in June 2025. The proceeds are expected to extend Xilio's anticipated cash runway into the second quarter of 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL7ZgZm1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4585","BK4588","NDAQ","XLO","LU0314104364.USD","SG9999014021.USD","BK4139","IE00B64PRP62.GBP","BK4112","SG9999014005.SGD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2601362921","title":"Press Release: Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2601362921","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601362921?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:30","pubTimestamp":1767879000,"startTime":"0","endTime":"0","summary":"Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027. Achieved development milestone for masked antibody-based program under AbbVie agreement. Nominated development candidate for wholly-owned masked T cell engager program targeting CLDN18.2. Appoints Sara Bonstein as chair of board of directors. WALTHAM, Mass., Jan. 08, 2026  -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today highlighted upcoming milestones and recent corporate updates.In January 2026, Xilio announced the receipt of $35.8 million in gross proceeds from the exercise of Series B warrants, before deducting underwriting discounts and commissions and any offering expenses, including the full exercise of Series B warrants held by Coa","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","XLO","LENZ","IND","BK4007"],"gpt_icon":0},{"id":"2601858913","title":"Xilio Therapeutics SVP Kevin M. Brennan Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601858913","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601858913?lang=en_us&edition=fundamental","pubTime":"2026-01-06 06:26","pubTimestamp":1767652014,"startTime":"0","endTime":"0","summary":"Kevin M. Brennan, SVP, Finance and Accounting, reported a disposal of common shares of Xilio Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLbTRZC3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xilio Therapeutics SVP Kevin M. Brennan Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2601884361","title":"Xilio Therapeutics Raises $35.8 Million From Series B Warrant Exercises","url":"https://stock-news.laohu8.com/highlight/detail?id=2601884361","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601884361?lang=en_us&edition=fundamental","pubTime":"2026-01-05 21:31","pubTimestamp":1767619881,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics Inc. announced that, following a June 2025 public offering, 48,207,815 Series B warrants were exercised through December 31, 2025, resulting in the issuance of 8,202,815 shares of common stock and 40,005,000 prefunded warrants. The company raised $35.8 million in gross proceeds from these exercises. Additionally, 66,676,000 Series C warrants were issued in connection with the offering, with 48,207,815 Series C warrants remaining outstanding. If all outstanding Series C warrants are exercised at their current price of $0.75 per warrant, Xilio could receive up to $36.2 million in additional gross proceeds by the end of 2026. As of January 2, 2026, Xilio had 67,540,930 shares of common stock outstanding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financia","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLbhrLsX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2586409363","title":"Xilio Therapeutics Inc. held special shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586409363","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586409363?lang=en_us&edition=fundamental","pubTime":"2025-11-26 05:06","pubTimestamp":1764104779,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics Inc. held a special meeting of stockholders on November 21, 2025. Stockholders approved a one-time repricing of certain outstanding employee stock options. Approval was also given for the 2025 Stock Incentive Plan. In addition, stockholders approved the proposal to allow adjournment of the special meeting if necessary.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL6rnmWy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2584492287","title":"Xilio Therapeutics Q3 Net Income USD -16.287 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584492287","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584492287?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:37","pubTimestamp":1763573856,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Xilio Therapeutics Q3 income from operations USD -1.929 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 13-NOV-202512:00:00.157 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD9grDsN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","BK4139"],"gpt_icon":0},{"id":"2584929288","title":"Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annua","url":"https://stock-news.laohu8.com/highlight/detail?id=2584929288","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584929288?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:06","pubTimestamp":1763571986,"startTime":"0","endTime":"0","summary":"Nov 7 (Reuters) - Xilio Therapeutics Inc ::*XILIO THERAPEUTICS ANNOUNCES LATE-BREAKING PHASE 2 DATA FOR VILASTOBART IN PATIENTS WITH MSS MCRC AND HIGH PLASMA TUMOR MUTATIONAL BURDEN AT SOCIETY FOR IMM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2RDD4b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2583254807","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Applied Therapeutics (APLT) and Xilio Therapeutics (XLO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583254807","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583254807?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:50","pubTimestamp":1763074211,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Applied Therapeutics (APLT – Research Report) and Xilio Therapeut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-applied-therapeutics-aplt-and-xilio-therapeutics-xlo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-applied-therapeutics-aplt-and-xilio-therapeutics-xlo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","APLT","LU0889565916.HKD","BK4588","BK4137","LABU","HCSG","LU0128526141.USD","LU0029874061.USD","XBI","XLO","BK4139","LU0109394709.USD","XLV","BK4585","BK4581"],"gpt_icon":0},{"id":"2583608525","title":"Xilio Therapeutics' Q3 collaboration revenue rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2583608525","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583608525?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:42","pubTimestamp":1763037734,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics' Q3 collaboration revenue risesOverviewXilio Q3 collaboration revenue rises to $19.1 mln from $2.3 mln year-over-yearNet loss for Q3 widens to $16.3 mln from $14.0 mln year-over-yea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0HR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2583604567","title":"BRIEF-Xilio Therapeutics Q3 Net Income USD -16.287 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583604567","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583604567?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037046,"startTime":"0","endTime":"0","summary":"BRIEF-Xilio Therapeutics Q3 Net Income USD -16.287 Million\n\n\nNov 13 (Reuters) - Xilio Therapeutics Q3 income from operations USD -1.929 million.\n\nQ3 operating expenses USD 20.995 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX15AA63:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2583671415","title":"Xilio Therapeutics Inc - Anticipates Cash Runway Into Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2583671415","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583671415?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX15AA63:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2583679215","title":"Press Release: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583679215","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583679215?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:30","pubTimestamp":1763037000,"startTime":"0","endTime":"0","summary":"Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden. Presented Phase 1 data at SITC for efarindodekin alfa showing promising monotherapy anti-tumor activity and generally well-tolerated safety profile in patients with advanced solid tumors. Announced new preclinical data at SITC for masked T cell engager programs supporting best-in-class potential and showing efficient masking, potent anti-tumor activity and broad therapeutic index. Anticipate cash runway into the first quarter of 2027. WALTHAM, Mass., Nov. 13, 2025  -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the third quarter ended September 30, 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4231","SITC","BK4539","BK4232","XLO","MSS","BK4080","ORR","R","BK4022","BK4585","BK4588","BK4107","LU2487616109.SGD","LU0210528500.USD","BK4007","LENZ","LU0053666078.USD","TMB","BK4113","L"],"gpt_icon":0},{"id":"2581881331","title":"Xilio Therapeutics presents new data across portfolio at SITC","url":"https://stock-news.laohu8.com/highlight/detail?id=2581881331","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581881331?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:21","pubTimestamp":1762525283,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics (XLO) announced new data across its portfolio, including preclinical data highlighting the potential for Xilio’s masked T cell e...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xilio-therapeutics-presents-new-data-across-portfolio-at-sitc-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xilio-therapeutics-presents-new-data-across-portfolio-at-sitc-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","LENZ","BK4139","XLO"],"gpt_icon":0},{"id":"2581881389","title":"Xilio Therapeutics announces new data on Phase 2 trial of vilastobart","url":"https://stock-news.laohu8.com/highlight/detail?id=2581881389","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581881389?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:20","pubTimestamp":1762525251,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics (XLO) announced new data from its ongoing Phase 2 clinical trial evaluating vilastobart, a tumor-activated, Fc-enhanced anti-CTL...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xilio-therapeutics-announces-new-data-on-phase-2-trial-of-vilastobart-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xilio-therapeutics-announces-new-data-on-phase-2-trial-of-vilastobart-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XLO","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"2581488650","title":"Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients With Mss Mcrc and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40TH Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581488650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581488650?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:05","pubTimestamp":1762524300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA4NN4CP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2581628886","title":"Press Release: Xilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2581628886","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581628886?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:05","pubTimestamp":1762524300,"startTime":"0","endTime":"0","summary":"40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden . Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need. \"These compelling new Phase 2 data for vilastobart in combination with atezolizumab demonstrated a 40% objective response rate in heavily pre-pretreated patients with MSS mCRC without liver metastases and with high plasma TMB, signifying an important advance in our understanding of response to novel immunotherapy in MSS mCRC,\" said Katarina Luptakova, M.D., chief medical officer of Xilio. \"In addition, these data showed a statistically significant correlation between plasma-based TMB and response. We estimate that approximately 55% of patients with MSS CRC have high plasma TMB, representing a meaningful patient population who could ultimately benefit from combination treatment with vilastobart and a substantially greater prevalence of patients w","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["L","BK4548","01308","BK4552","BK4565","TME","BK4108","BK4139","IE00BYTNYN87.SGD","BK4007","LU2487616109.SGD","BK4588","MSS","BK4232","IE0003795394.USD","LU0053666078.USD","LU2039709279.SGD","BK4509","TMB","LU0359202008.SGD","LU1023057109.AUD","LU0210528500.USD","BK1541","BK4563","BK4526","IE0003851619.USD","BK1103","BK4231","SITC","IE00BYQNZ168.SGD","BK4571","BK4585","R","LENZ","BK4535","IE00B12V2V27.USD","01698","BK4080","ORR","BK4113","BK4022","BK4107","LU0456842615.SGD","SG9999011746.SGD","BK4539","BK4531","XLO","LU0359201612.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xiliotx.com","stockEarnings":[{"period":"1week","weight":-0.1153},{"period":"1month","weight":-0.0152},{"period":"3month","weight":-0.1387},{"period":"6month","weight":-0.1134},{"period":"1year","weight":-0.4073},{"period":"ytd","weight":-0.0002}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.103},{"period":"1year","weight":0.1678},{"period":"ytd","weight":0.0151}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.025477},{"month":2,"riseRate":0.5,"avgChangeRate":0.057614},{"month":3,"riseRate":0.25,"avgChangeRate":-0.049721},{"month":4,"riseRate":0.5,"avgChangeRate":-0.109931},{"month":5,"riseRate":0.5,"avgChangeRate":0.052494},{"month":6,"riseRate":0,"avgChangeRate":-0.163729},{"month":7,"riseRate":0.5,"avgChangeRate":0.01036},{"month":8,"riseRate":0.5,"avgChangeRate":-0.060444},{"month":9,"riseRate":0.5,"avgChangeRate":0.039039},{"month":10,"riseRate":0.5,"avgChangeRate":0.099935},{"month":11,"riseRate":0.2,"avgChangeRate":-0.160439},{"month":12,"riseRate":0.4,"avgChangeRate":-0.10922}],"exchange":"NASDAQ","name":"XILIO THERAPEUTICS, INC.","nameEN":"XILIO THERAPEUTICS, INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"XILIO THERAPEUTICS, INC.(XLO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest XILIO THERAPEUTICS, INC.(XLO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"XILIO THERAPEUTICS, INC.,XLO,XILIO THERAPEUTICS, INC.股票,XILIO THERAPEUTICS, INC.股票老虎,XILIO THERAPEUTICS, INC.股票老虎国际,XILIO THERAPEUTICS, INC.行情,XILIO THERAPEUTICS, INC.股票行情,XILIO THERAPEUTICS, INC.股价,XILIO THERAPEUTICS, INC.股市,XILIO THERAPEUTICS, INC.股票价格,XILIO THERAPEUTICS, INC.股票交易,XILIO THERAPEUTICS, INC.股票购买,XILIO THERAPEUTICS, INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"XILIO THERAPEUTICS, INC.(XLO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest XILIO THERAPEUTICS, INC.(XLO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction